Literature DB >> 23794648

Neuropathic pain: a pathway for care developed by the British Pain Society.

B H Smith1, J Lee, C Price, A P Baranowski.   

Abstract

Neuropathic pain is a common chronic pain condition that can be challenging to treat, particularly for non-specialists. The development of the Map of Medicine care pathway for the management of neuropathic pain was led by the British Pain Society. Focusing on treatment by non-specialists, this pathway is based on new evidence, consensus, and the interests of service users. This paper presents the care pathway and accompanying evidence base, highlighting its salient features, and discussing important treatment points. After initial assessment, the pathway progresses through first-, second-, and third-line drug treatment, includes advice on topical treatment and opioids (in specific circumstances), and describes non-pharmacological approaches. Importantly, timely review of patients and referral to specialist secondary or tertiary care must be considered as vital components of the pathway. Although the emphasis was not on specialist treatment, advice is given on existing interventions, including neural stimulation and multi-disciplinary care. These, and other steps on the pathway, will be subject to further review as more evidence becomes available. In the meantime, the pathway represents a straightforward, valuable and accessible approach for healthcare professionals managing the distress and impact of neuropathic pain.

Entities:  

Keywords:  nerve pain; neuralgia; neuropathic pain

Mesh:

Substances:

Year:  2013        PMID: 23794648     DOI: 10.1093/bja/aet206

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  9 in total

Review 1.  Drug therapy for chronic idiopathic axonal polyneuropathy.

Authors:  Janna Warendorf; Alexander Fje Vrancken; Ivo N van Schaik; Richard Ac Hughes; Nicolette C Notermans
Journal:  Cochrane Database Syst Rev       Date:  2017-06-20

2.  Inhaled hydrogen sulfide prevents neuropathic pain after peripheral nerve injury in mice.

Authors:  Kotaro Kida; Eizo Marutani; Rebecca K Nguyen; Fumito Ichinose
Journal:  Nitric Oxide       Date:  2014-11-24       Impact factor: 4.427

3.  Peoples' experiences of painful diabetic neuropathy: are pain management programmes appropriate?

Authors:  Ben Davies; Fiona Cramp; Jeremy Gauntlett-Gilbert; Candida S McCabe
Journal:  Br J Pain       Date:  2021-01-31

Review 4.  Topical clonidine for neuropathic pain in adults.

Authors:  Wojciech T Serednicki; Anna Wrzosek; Jaroslaw Woron; Jaroslaw Garlicki; Jan Dobrogowski; Joanna Jakowicka-Wordliczek; Jerzy Wordliczek; Renata Zajaczkowska
Journal:  Cochrane Database Syst Rev       Date:  2022-05-19

5.  Neuropathic pain responds better to increased doses of pregabalin: an in-depth analysis of flexible-dose clinical trials.

Authors:  Michael Serpell; Mark Latymer; Mary Almas; Marie Ortiz; Bruce Parsons; Rita Prieto
Journal:  J Pain Res       Date:  2017-07-26       Impact factor: 3.133

6.  CSF levels of apolipoprotein C1 and autotaxin found to associate with neuropathic pain and fibromyalgia.

Authors:  Anne-Li Lind; David Just; Maria Mikus; Claudia Fredolini; Marina Ioannou; Björn Gerdle; Bijar Ghafouri; Emmanuel Bäckryd; Lars Tanum; Torsten Gordh; Anna Månberg
Journal:  J Pain Res       Date:  2019-10-15       Impact factor: 3.133

Review 7.  Topical clonidine for neuropathic pain.

Authors:  Anna Wrzosek; Jaroslaw Woron; Jan Dobrogowski; Joanna Jakowicka-Wordliczek; Jerzy Wordliczek
Journal:  Cochrane Database Syst Rev       Date:  2015-08-31

Review 8.  The clinical approach to small fibre neuropathy and painful channelopathy.

Authors:  Andreas C Themistocleous; Juan D Ramirez; Jordi Serra; David L H Bennett
Journal:  Pract Neurol       Date:  2014-04-28

9.  Melatonin MT2 receptor agonist IIK-7 produces antinociception by modulation of ROS and suppression of spinal microglial activation in neuropathic pain rats.

Authors:  Yaswanth Kuthati; Venkata Naga Goutham Davuluri; Chih-Ping Yang; Hsiao-Cheng Chang; Chih-Peng Chang; Chih Shung Wong
Journal:  J Pain Res       Date:  2019-08-08       Impact factor: 3.133

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.